BioSpace News Archive

Aperio Clinical Outcomes announced that industry veteran Jennifer Hodak has joined the company as Director of Talent Acquisition as they scale-up to support the growing needs of their pharmaceutical, biotech and medical device client base.

Spencer Trask & Co., a privately held advanced technology development firm, announced it has partnered with Rotary International and the World Health Organization to crowdsource a global call-to-action for seeking innovative solutions to curtail the spread of online misinformation that is purposely thwarting efforts to eradicate polio in Pakistan.

Organoids, grown from stem cells, are tiny 3D formations of human tissue that actually perform the functions of multiple cells types found in full-sized organs

Between 12 and 20 percent of Americans over age 60 have peripheral arterial disease.

Stanford Children’s Health announced that it has achieved Magnet recognition as a reflection of its exemplary professional nursing practice, interprofessional teamwork and preeminent patient care.

Health systems must view their physician enterprise as a critical strategic business unit

Feinstein Institutes for Medical Research Professor David Eidelberg, MD, has received a five-year, $2.9 million grant from the National Institutes of Health (NIH) to support his research in developing a way to delay or prevent negative effects of a common treatment in those with Parkinson’s disease.

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019 Congress on Saturday, Sept. 28, at 10 a.m. PT.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference in New York, NY.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline results from its ARGON-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).